Other notable subtypes include SDH-deficient, ALK-rearranged (responsive to ALK inhibitors), ELOC (TCEB1)-mutated, and highly aggressive SMARCB1-deficient RCC [26]. Here, ELOC is linked to renal cell carcinoma.